



**To:** MaineCare Providers  
**From:** Jill Kingsbury, Director of Pharmacy  
**Date:** January 22, 2019  
**Re:** PDL Update for **01/25/2019**

The following medications have been recently added/changed to the MaineCare PDL as non-preferred and will require prior authorization.

|         |           |          |          |          |
|---------|-----------|----------|----------|----------|
| Altreno | Delstrigo | Nivestym | Perseris | Pifeltro |
| Plixda  | Roxybond  | Takhzyro | Xofluza  | Ztlido   |

The following medication has been recently added/changed to the MaineCare PDL as preferred and will *not* require prior authorization.

|         |                |
|---------|----------------|
| Firvanq | Lidocaine Ptch |
|---------|----------------|

The following medication have been recently added to the MaineCare PDL as well as new PDL criteria.

**Aimovig, Ajovy and Emgality** are non-preferred and approvals will be available for chronic migraine defined as 15 or more headaches a month. Adequate trial of three preventative treatment medications of 60 days each.

**Braftovi** is non-preferred and approvals will require a clinical prior authorization for appropriate diagnosis and testing. DDI: Braftovi, Cometriq, Ibrance, Tafinlar and Tibsovo will require a prior authorization if it is currently being used in combination with drugs known to be significant CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, atazanavir, saquinavir and telithromycin).

**Lumoxiti** is non-preferred and approvals will require a clinical prior authorization for appropriate diagnosis and testing. Lumoxiti is indicated for the treatment of adults with relapsed or refractory hairy cell leukemia who received at least 2 prior systemic therapies, including treatment with a purine nucleoside analog.

**Libtayo, Mektovi, Talzena and Tibsovo** are non-preferred and approvals will require a clinical prior authorization for appropriate diagnosis and testing.

**Vizimpro** is non-preferred and approvals will require a clinical prior authorization for appropriate diagnosis and testing. Vizimpro and concomitant use with a PPI decreased dacomitinib concentrations. DDI: Vizimpro® increases the concentration of drugs that are CYP2D6 substrates, which may increase the risk of toxicities of these drugs Thus, avoid the concomitant use.

**Doptelet and Mulpleta** are non-preferred and for the treatment of thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.

**Epidiolex** is non-preferred and is for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older. Criteria for Lennox-Gastaut syndrome (LGS): a trial of three drugs

If you have any questions, please contact Change Healthcare at 1-888-420-9711.

---

(two preferred drugs and then either Banzel or clobazam). Criteria for Dravet syndrome: previous trial of clobazam with valproic acid in patients not adequately controlled on monotherapy.

**Ilumya** is non-preferred and is for the treatment of adults with moderate-to- severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

**Jivi** is non-preferred and is not indicated for use in children <12 years of age due to greater risk for hypersensitivity reactions and is not indicated for use in previously untreated patients.

**Lokelma** is non-preferred and is for the treatment of acute hyperkalemia in patients unable to tolerate sodium polystyrene sulfonate.

**Nocturna** is non-preferred and products in this category must be used in specified step order. Nocturnal enuresis patients will be encouraged to periodically attempt stopping DDAVP.

**Orilissa** is non-preferred and prior treatment of NSAID and hormonal contraceptives are required.

**Trospium** is non-preferred and will be moved to the Antispasmodic- Long Acting category.

**Fluoroplex cream, Omontys, Systane** are being removed from the PDL as they are no longer available.

**Hereditary Angioedema** category on the MaineCare PDL has been split into two sub-categories Prophylaxis and Treatment.

**If you have any questions, please contact Change Healthcare at 1-888-420-9711.**

---